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The current special topics issue of Frontiers in Neuroscience
“Insomnia and Beyond—Exploring the Therapeutic Potential of
Orexin Receptor Antagonists” comprises 20 papers from lead-
ers in the orexin/hypocretin field presenting their latest findings
and thorough reviews, and will undoubtedly serve as an impor-
tant reference for others engaged in this field of study. Since
the independent identification of the orexin/hypocretin system in
1998 by two teams investigating hypothalamic signaling (de Lecea
et al., 1998; Sakurai et al., 1998), the field has rapidly expanded
to include potential roles of orexin in processes as diverse as
sleep/wake, addiction, feeding, pain and anxiety. Orexin neu-
ropeptides (OX-A, OX-B) are cleaved from a common precursor
and secreted from orexinergic neurons localized in the lateral
hypothalamus. Orexins (also passionately referred to as hypocre-
tins by many investigators) bind and activate two G-protein
coupled receptors (OX1R and OX2R), with OX-A binding equally,
and OX-B having ∼10 fold selectivity for OX2R. Although orex-
inergic neurons are localized to less than 100,000 hypothalamic
neurons in the human brain, orexin receptors exhibit overlap-
ping and distinct expression throughout the CNS, with significant
expression in brain regions associated with arousal and vigilance
state, as well as reward and stress processing.
Following their seminal discovery of this novel neuropeptide
system 16 years ago, authors of the foundational Proc. Natl. Acad.
Sci. and Cell papers joined by other exceptional researchers pro-
vide their latest insights into the function of orexin signaling and
its therapeutic potential.
Drs. de Lecea and Huerta (2014) explain their current view
on the interaction of orexin neurons with other neuromodula-
tory systems based on recent optogenetic experiments. A paper
from Kohlmeier et al. (2013) presents an original investigation
on the interaction of the orexin system with cholinergic and
monoaminergic neurons using OX1 and OX2 receptor knockout
mice. Two separate papers from Etori et al. (2014) and Tortorella
et al. (2013) provide insight into potential synaptic interactions
between the hypothalamus, locus coeruleus and oral pontine
reticular nucleus, suggesting that orexin signaling within this cir-
cuit modulates stage succession during sleep-wakefulness cycles.
Expanding upon the first observations of genetic disruptions of
orexin receptors in dogs, Thompson et al. (2014) provide a phar-
macogenetic overview of orexin peptides and their receptors,
and describe the potential impact of polymorphisms observed in
human genetic studies. Finally, work described in Flores et al.
(2013) illustrates cannabinoid-hypocretin cross-talk within the
CNS, an emerging area of interest for the field.
The identification of a neuropeptide system with restricted
expression, key functions in fundamental CNS processes and
approachability of discrete GPCR subtypes has made orexin
receptors valuable targets for the next generation of CNS
therapeutics, with multiple teams actively characterizing small
molecules to understand the pharmacology and potential ther-
apeutic applications of targeting the orexin system. Equihua
et al. (2013) takes the reader on a journey comparing the mer-
its and challenges of orexin receptor antagonists as potential sleep
medications relative to currently used hypnotics. A paper from
Callander et al. (2013) representing a team formerly at Novartis,
provides substantial in vitro characterization and describes dif-
ferential kinetic properties of dual orexin receptor antagonists
(DORAs) that have undergone clinical evaluation. Two pharma-
cological papers from Morairty et al. (2014) (work by groups
UCSF and SRI), and Ramirez et al. (2013) (Merck Research
Laboratories), demonstrate that DORAs lack the impairment
on motor and cognitive function in rodents exhibited by posi-
tive GABA-A receptor modulators. Etori et al. (2014) (Kanazawa
University), Dugovic et al. (2014) (Janssen), and Hoyer et al.
(2013) (team formerly at Novartis) explore the potential differ-
ential impact of DORAs as well as antagonists selective for OX1R
and OX2R on non-REM and REM sleep architecture.
With regard to other potential indications for OXR antag-
onists beyond insomnia, two manuscripts from teams at Lilly
Research Laboratories and MUSC (Anderson et al., 2014; Fitch
et al., 2014) describe a novel OX2R selective antagonist, and its
effects on rodent models of ethanol addiction and depression
relative to a DORA and OX1R selective antagonist. In addition,
(Steiner et al., 2013) (Actelion), investigated the impact of chronic
pharmacological OX1R blockade in a rat model of diet-induced
obesity.
A further area of orexin research which is being actively inves-
tigated focuses on the impact of orexin signaling on sympathetic
autonomous nervous system activation, both during sleep and
wake stages, as well as during heightened arousal and stress.
Two excellent reviews from leaders in the field (Carrive, 2013;
Li and Nattie, 2014) provide an overview of the current perspec-
tives regarding cardiovascular and respiratory control by orexins.
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(Colas et al., 2014) present evidence supporting the existence of
an orexin circuit between central and peripheral nervous system,
where orexin signaling potentially modulates sensory processing
at dorsal root ganglia.
Together with the increasing availability of pharmacological
tools, investigations of the role of orexin in limbic emotional
processing have also intensified during the last 3–4 years. Two
detailed reviews shed light on this topic, from both academic
and industry perspectives (Yeoh et al., 2014 from the University
of Newcastle and the Hunter Medical Research Institute; Merlo
Pich and Melotto, 2014, formerly of Glaxo Smith Kline). These
two papers outline recent findings from rodent studies identifying
involvement of orexins in mediating compulsive behavior, as well
as panic, depression and anxiety-like reactions during withdrawal
from drugs of abuse.
Importantly, this special issue highlights the exquisite founda-
tional and translational work being conducted by teams at leading
academic and biopharmaceutical laboratories, focused on investi-
gating a range of therapeutic opportunities. Although it has only
been 16 years since the identification of the orexin/hypocretin
system, the wealth of knowledge obtained thus far has set the
stage for the next decade of orexin research. It is with great
appreciation to the contributing authors and with much enthu-
siasm that we present this special topics issue of Frontiers in
Neuroscience.
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